Literature DB >> 8466485

Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries.

J A Winkles1, G F Alberts, E Brogi, P Libby.   

Abstract

Endothelin-1 (ET-1) is a potent vasoconstrictor peptide implicated in a number of human diseases including atherosclerosis. ET-1 binds to two distinct G protein-coupled receptors, known as the ETA and ETB receptor subtypes. In this study, we have examined ET-1, ETA and ETB mRNA expression levels in human vascular cells cultured in vitro and in normal and atherosclerotic human arteries. The results indicate that (a) ET-1 mRNA is constitutively expressed by endothelial cells but not by smooth muscle cells, (b) endothelial cells express only ETB mRNA but smooth muscle cells co-express ETA and ETB mRNA, and (c) in comparison to normal aorta, ET-1 mRNA expression is elevated and endothelin receptor mRNA expression is repressed in atherosclerotic lesions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8466485     DOI: 10.1006/bbrc.1993.1327

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

Review 1.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

2.  Two-year prognosis after acute coronary syndrome in younger patients: Association with feeling depressed in the prior year, and BDI-II score and Endothelin-1.

Authors:  Luba Yammine; Lorraine Frazier; Nikhil S Padhye; Jennifer E Sanner; Matthew M Burg
Journal:  J Psychosom Res       Date:  2017-05-23       Impact factor: 3.006

Review 3.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 4.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

5.  Severe depressive symptoms are associated with elevated endothelin-1 in younger patients with acute coronary syndrome.

Authors:  Luba Yammine; Lorraine Frazier; Nikhil S Padhye; Matthew M Burg; Janet C Meininger
Journal:  J Psychosom Res       Date:  2014-08-02       Impact factor: 3.006

6.  Tendency to angry rumination predicts stress-provoked endothelin-1 increase in patients with coronary artery disease.

Authors:  Antonio B Fernandez; Robert Soufer; Dorothea Collins; Aaron Soufer; Hooman Ranjbaran; Matthew M Burg
Journal:  Psychosom Med       Date:  2010-04-05       Impact factor: 4.312

Review 7.  The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.

Authors:  M Barton; W Kiowski
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

8.  Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.

Authors:  Martin Reriani; Eugenia Raichlin; Abhiram Prasad; Verghese Mathew; Geralyn M Pumper; Rebecca E Nelson; Ryan Lennon; Charanjit Rihal; Lilach O Lerman; Amir Lerman
Journal:  Circulation       Date:  2010-08-23       Impact factor: 29.690

9.  Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice.

Authors:  M Barton; C C Haudenschild; L V d'Uscio; S Shaw; K Münter; T F Lüscher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

10.  Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol.

Authors:  M C Kowala; P M Rose; P D Stein; N Goller; R Recce; S Beyer; M Valentine; D Barton; S K Durham
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.